You are here: Home > Prescription(RX) Drugs > P > Pancrelipase (Kaiser Foundation Hospitals)

Name:Pancrelipase
Manufacturer:Kaiser Foundation Hospitals
Category:Prescription Marketed Drugs


PANCRELIPASE  - pancrelipase lipase, pancrelipase amylase and pancrelipase protease capsule, delayed release 
KAISER FOUNDATION HOSPITALS

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

DESCRIPTION

Pancrelipase 20,000 capsules are orally administered and contain delayed-release microspheres of porcine pancreatic enzyme concentrate, predominantly pancreatic lipase, amylase and protease.

Each 20,000 capsule contains:

Lipase 20,000 USP Units

Amylase 56,000 USP Units

Protease 44,000 USP Units

Inactive Ingredients:

Diethyl Phthalate NF, Hydroxypropyl Methylcellulose USP, Hypromellose Phthalate NF, Polyethylene Glycol NF, and Povidone USP.

CLINICAL PHARMACOLOGY

Pancrelipase capsules resist gastric inactivation and deliver predicable, high levels of biologically active enzymes into the duodenum. The enzymes catalyze the hydrolysis of fats into glycerol and fatty acids, protein into proteoses and derived substances, and starch into dextrins and sugars. Pancrelipase capsules are effective in controlling steatorrhea and its consequences at low daily dosage levels.

INDICATIONS AND USAGE

Pancrelipase capsules are indicated for patients with exocrine pancreatic enzyme deficiency as in but not limited to: cystic fibrosis, chronic pancreatitis, post-pancreatectomy,  post-gastrointestinal bypass surgery (e.g. Billroth II gastroenterostomy), ductal obstruction from neoplasm (e.g. of the pancreas or common bile duct).

CONTRAINDICATIONS

Pancrelipase capsules are contraindicated in patients known to be hypersensitive to pork protein.

Pancrelipase capsules are contraindicated in patients with acute pancreatitis or with acute exacerbations of chronic pancreatic diseases.

WARNINGS

Should hypersensitivity occur, discontinue medication and treat symptomatically.

PRECAUTIONS

TO PROTECT ENTERIC COATING, MICROSPHERES SHOULD NOT BE CRUSHED OR CHEWED.

Where swallowing of capsules is difficult, they may be opened and the microspheres shaken into a small quantity of a soft food (e.g. applesauce, gelatin, etc.), which does not require chewing, and swallowed immediately. Contact of the microspheres with foods having a pH greater than 5.5 can dissolve the protective enteric shell.

Pregnancy Category C.
Diethylphthalate, an enteric coating component of pancrelipase capsules has been shown with high intraperitoneal dosing to be teratogenic in rats. However, when this coating was administered orally to rats up to 100 times the human dose, no teratogenic or embryocidal effects were observed. There were no adequate and well-controlled studies in pregnant women. Pancrelipase capsules should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

Cases of fibrotic stricture in the ascending colon have been reported in cystic fibrosis patients with the use of enzyme supplements in high doses (approximately 6,500 - 50,000 USP lipase units/kg/meal). If symptoms suggestive to gastrointestinal obstruction occur, the possibility of bowl strictures should be considered.

ADVERSE REACTIONS



The most frequently reported adverse reaction to pancrelipase capsules are gastrointestinal in nature. Less frequently, allergic-type reactions have also been observed. Extremely high doses of exogenous pancreatic enzymes have been associated with hyperuricosuria and hyperuricemia when the preparations given were pancrelipase in powedered or capsule form, or pancreatin in tablet form.

DOSAGE AND ADMINISTRATION

Dosage should be adjusted according to the severity of the exocrine pancreatic enzyme deficiency. The number of capsules or capsule strength given with meals and/or snacks should be estimated by assessing which dose minimizes steatorhea and maintains good nutritional status. Dose increases if required, should be made slowly, with careful monitoring of response and symptomatology. It is important to ensure adequate hydration of patients at all times while dosing Pancrelipase capsules. In some patients with pancreatic enzyme deficiency, satisfactory responses have been achieved with dosages (expressed in U.S.P. units of lipase) similar to the ones stated below. However, dosages should be adjusted according to the response of the patient.

Children 7 to 12 years: 4,000 to 12,000 units (more if necessary) with each meal and with snacks.

Children 1 to 6 years: 4,000 to 8,000 units with each meal and 4,000 units with snacks.

Children under 1 year: Dosage for children under 6 months of age has not been established. Children 6 months to 1 year have responded to 2,000 units of lipase per meal.

The assessment of the end points in children is aided by charting growth curves.

Adults: 4,000 to 20,000 units (more if necessary) with each meal and with snacks.

HOW SUPPLIED

PANCRELIPASE 20,000 Capsules- flesh, natural; printed EUR 20,000  30 capsules in 1 Box, Unit-Dose.

Store below 25°C (77°F) in a dry place.

Do not refrigerate.

No studies have been performed to determine equivalence of this product with any other products with the same or similar co-enzyme content or ratio and no such claims are intended.

Rx only.

Manufactured by:
EURAND Inc.
Vandalia, OH 45377

Distributed by:
X-GEN Pharmaceuticals, Inc.
Big Flats, NY 14814

Repackaged by:
KAISER FOUNDATION HOSPITALS
Livermore, CA  94551

Package Label-Pancrelipase 20,000


PANCRELIPASE 
pancrelipase capsule, delayed release
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0179-0020(NDC:39822-9200)
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
PANCRELIPASE LIPASE (PANCRELIPASE) PANCRELIPASE LIPASE 20000 [USP'U]
PANCRELIPASE AMYLASE (PANCRELIPASE) PANCRELIPASE AMYLASE 56000 [USP'U]
PANCRELIPASE PROTEASE (PANCRELIPASE) PANCRELIPASE PROTEASE 44000 [USP'U]
Inactive Ingredients
Ingredient Name Strength
DIETHYL PHTHALATE  
HYPROMELLOSE  
HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)  
POLYETHYLENE GLYCOL  
POVIDONE  
Product Characteristics
Color pink (FLESH, NATURAL) Score no score
Shape CAPSULE Size 24mm
Flavor Imprint Code EUR;20000
Contains     
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0179-0020-70 30 CAPSULE, DELAYED RELEASE ( CAPSULE) in 1 BOX, UNIT-DOSE None

Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
unapproved drug other 02/01/2010

Labeler - KAISER FOUNDATION HOSPITALS (053052619)
Establishment
Name Address ID/FEI Operations
KAISER FOUNDATION HOSPITALS 053052619 repack

Revised: 08/2010 KAISER FOUNDATION HOSPITALS



Source: http://dailymed.nlm.nih.gov
Reproduced with permission of U.S. National Library of Medicine


Copyright © 2017 Drugsdb.eu by Dionisios Fentas || Terms of Use

Loading

Prescription Marketed Drugs Alphabetically
A| B| C| D| E| F| G| H| I| J| K| L| M| N| O| P| Q| R| S| T| U| V| W| X| Y| Z| 0-9

Categories:
Prescription(RX) Drugs
Over-the-counter (OTC) Drugs
Homeopathic Drugs
Animal Drugs
Feedback